Suppr超能文献

糖尿病的神经肌肉并发症

Neuromuscular complications of diabetes mellitus.

作者信息

Bril Vera

出版信息

Continuum (Minneap Minn). 2014 Jun;20(3 Neurology of Systemic Disease):531-44. doi: 10.1212/01.CON.0000450964.30710.a0.

Abstract

PURPOSE OF REVIEW

Diabetes mellitus has become a modern global epidemic, with steadily increasing prevalence rates related to lifestyle such that 27% of individuals aged 65 years or older have diabetes mellitus, 95% of whom have type 2. This article reviews the effects of diabetes mellitus on the neuromuscular system.

RECENT FINDINGS

Diabetes mellitus leads to diverse forms of peripheral neuropathy as the major neuromuscular complication. Both focal and diffuse types of neuropathy can develop, with the most common form being diabetic sensorimotor polyneuropathy. Small fibers are damaged early in the development of diabetic sensorimotor polyneuropathy and are not assessed by nerve conduction studies. Small fiber damage occurs even in the prediabetes stage. No disease-modifying therapy for diabetic sensorimotor polyneuropathy is available at this time, but this complication can be limited in patients who have type 1 diabetes mellitus with strict glycemic control; the same outcome is not clearly observed in patients who have type 2 diabetes mellitus. Recently, the evidence base for symptomatic treatments of painful diabetic sensorimotor polyneuropathy underwent systematic review. Effective evidence-based treatments include some anticonvulsants (eg, pregabalin, gabapentin), antidepressants (eg, amitriptyline, duloxetine), opioids (eg, morphine sulfate, oxycodone), capsaicin cream, and transcutaneous electrical nerve stimulation.

SUMMARY

This article reviews the increasing prevalence of diabetes mellitus and diabetic sensorimotor polyneuropathy and discusses recent consensus opinion on the objective confirmation needed for the diagnosis in the clinical research setting. The evidence from clinical trials shows that intensive glycemic control reduces prevalence of diabetic sensorimotor polyneuropathy in patients with type 1 diabetes mellitus, but variable outcomes are observed in patients with type 2 diabetes mellitus. Finally, despite the lack of disease-modifying treatment, effective evidence-based therapy can control painful symptoms of diabetic sensorimotor polyneuropathy.

摘要

综述目的

糖尿病已成为一种现代全球性流行病,其患病率因生活方式的影响而稳步上升,65岁及以上人群中有27%患有糖尿病,其中95%为2型糖尿病。本文综述糖尿病对神经肌肉系统的影响。

最新发现

糖尿病会引发多种形式的周围神经病变,这是主要的神经肌肉并发症。局灶性和弥漫性神经病变均可发生,最常见的形式是糖尿病性感觉运动性多发神经病变。在糖尿病性感觉运动性多发神经病变发展早期,小纤维就会受损,而神经传导研究无法对此进行评估。即使在糖尿病前期阶段,小纤维也会受损。目前尚无针对糖尿病性感觉运动性多发神经病变的疾病改善疗法,但对于1型糖尿病患者,严格控制血糖可限制该并发症;在2型糖尿病患者中,尚未明确观察到同样的结果。最近,对疼痛性糖尿病性感觉运动性多发神经病变的对症治疗证据基础进行了系统评价。有效的循证治疗包括一些抗惊厥药(如普瑞巴林、加巴喷丁)、抗抑郁药(如阿米替林、度洛西汀)、阿片类药物(如硫酸吗啡、羟考酮)、辣椒素乳膏和经皮电刺激神经疗法。

总结

本文综述了糖尿病和糖尿病性感觉运动性多发神经病变患病率的上升情况,并讨论了临床研究中诊断所需客观确认的近期共识意见。临床试验证据表明,强化血糖控制可降低1型糖尿病患者糖尿病性感觉运动性多发神经病变的患病率,但2型糖尿病患者的结果各异。最后,尽管缺乏疾病改善治疗,但有效的循证疗法可控制糖尿病性感觉运动性多发神经病变的疼痛症状。

相似文献

1
Neuromuscular complications of diabetes mellitus.
Continuum (Minneap Minn). 2014 Jun;20(3 Neurology of Systemic Disease):531-44. doi: 10.1212/01.CON.0000450964.30710.a0.
2
Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia.
Cochrane Database Syst Rev. 2014 Jan 3;2014(1):CD007115. doi: 10.1002/14651858.CD007115.pub3.
3
The Black Book of Psychotropic Dosing and Monitoring.
Psychopharmacol Bull. 2024 Jul 8;54(3):8-59.
4
Antiepileptic drugs for chronic non-cancer pain in children and adolescents.
Cochrane Database Syst Rev. 2017 Aug 5;8(8):CD012536. doi: 10.1002/14651858.CD012536.pub2.
5
Enhanced glucose control for preventing and treating diabetic neuropathy.
Cochrane Database Syst Rev. 2012 Jun 13;2012(6):CD007543. doi: 10.1002/14651858.CD007543.pub2.
6
Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus.
Cochrane Database Syst Rev. 2014 Feb 14;2014(2):CD009122. doi: 10.1002/14651858.CD009122.pub2.
7
Oxycodone for neuropathic pain in adults.
Cochrane Database Syst Rev. 2016 Jul 28;7(7):CD010692. doi: 10.1002/14651858.CD010692.pub3.
9
Antidepressants for pain management in adults with chronic pain: a network meta-analysis.
Health Technol Assess. 2024 Oct;28(62):1-155. doi: 10.3310/MKRT2948.

引用本文的文献

3
Case report: Corticosteroids-induced acute diabetic peripheral neuropathy.
Front Endocrinol (Lausanne). 2022 Aug 3;13:914325. doi: 10.3389/fendo.2022.914325. eCollection 2022.
4
Diabetic neuropathy research: from mouse models to targets for treatment.
Neural Regen Res. 2019 Nov;14(11):1870-1879. doi: 10.4103/1673-5374.259603.
5
Acupoint Therapy on Diabetes Mellitus and Its Common Chronic Complications: A Review of Its Mechanisms.
Biomed Res Int. 2018 Oct 22;2018:3128378. doi: 10.1155/2018/3128378. eCollection 2018.
6
Overexpression of KLF5 inhibits puromycin‑induced apoptosis of podocytes.
Mol Med Rep. 2018 Oct;18(4):3843-3849. doi: 10.3892/mmr.2018.9366. Epub 2018 Aug 9.
7
Hypoglycemic Effect of Jicama (Pachyrhizus erosus) Extract on Streptozotocin-Induced Diabetic Mice.
Prev Nutr Food Sci. 2015 Jun;20(2):88-93. doi: 10.3746/pnf.2015.20.2.88. Epub 2015 Jun 30.
8
Neuromuscular issues in systemic disease.
Curr Neurol Neurosci Rep. 2015 Jul;15(7):48. doi: 10.1007/s11910-015-0565-x.

本文引用的文献

3
Neuropathy.
Can J Diabetes. 2013 Apr;37 Suppl 1:S142-4. doi: 10.1016/j.jcjd.2013.01.039. Epub 2013 Mar 26.
4
Conduction slowing in diabetic sensorimotor polyneuropathy.
Diabetes Care. 2013 Nov;36(11):3684-90. doi: 10.2337/dc13-0746. Epub 2013 Sep 11.
7
Whither pathogenetic treatments for diabetic polyneuropathy?
Diabetes Metab Res Rev. 2013 Jul;29(5):327-33. doi: 10.1002/dmrr.2397.
8
Type 2 diabetes: increased mortality with low HbA1c.
Prescrire Int. 2013 Jan;22(134):23.
10
Enhanced glucose control for preventing and treating diabetic neuropathy.
Cochrane Database Syst Rev. 2012 Jun 13;2012(6):CD007543. doi: 10.1002/14651858.CD007543.pub2.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验